ZTE Announces RMB 2.4 Billion Proposed Funding in Subsidiary by New Investor
ZTE Corporation (0763.HK / 000063.SZ), a major international provider of telecommunications, enterprise and consumer technology solutions for the Mobile Internet, announced that its ZTE Microelectronics Technology Company Ltd. subsidiary had agreed to a proposed RMB 2.4 billion (USD 376 million) investment by National Integrated Circuit Industry Investment Fund Corporation.
Under the agreement, National Integrated Circuit Industry Investment Fund will acquire 24% of the enlarged shareholding of ZTE Microelectronics. The new investment will enhance ZTE Microelectronics’ research and development capabilities, and strengthen its offerings in advanced semiconductor technologies, as well as broaden its marketing and distribution channels in China and in international markets.
ZTE Microelectronics focuses on the development of semiconductor technologies for applications including telecommunications, mobile devices, Big Data, cloud computing, Internet of Things and wearables. With more than 2,000 R&D employees in offices in China and the United States, ZTE Microelectronics is currently developing products with 28 nanometer technologies, and has R&D capabilities for 16 nanometer and 14 nanometer technologies.
Chipsets developed by ZTE Microelectronics are currently deployed commercially in base stations to support multi-frequency band wireless access, as well as optical networking units (ONUs). In addition, ZTE Microelectronics also develops products used in smartphones and mobile devices shipped in markets including China, Brazil, Indonesia and Russia, supporting LTE-Advanced standards and multimode operations.
In 2014, ZTE Microelectronics increased its net profit by 258% to RMB 458.6 million, with revenue growing to RMB 3.06 billion.
National Integrated Circuit Industry Investment Fund, with shareholders including China’s Ministry of Finance, China Development Bank and China Mobile Communications Corporation, has investments in developers of semiconductor technologies, an area of national strategic interest to the Chinese government.
ZTE is a provider of advanced telecommunications systems, mobile devices, and enterprise technology solutions to consumers, carriers, companies and public sector customers. As part of ZTE’s M-ICT strategy, the company is committed to provide customers with integrated end-to-end innovations to deliver excellence and value as the telecommunications and information technology sectors converge. Listed in the stock exchanges of Hong Kong and Shenzhen (H share stock code: 0763.HK / A share stock code: 000063.SZ), ZTE’s products and services are sold to over 500 operators in more than 160 countries. ZTE commits 10 per cent of its annual revenue to research and development and has leadership roles in international standard-setting organizations. ZTE is committed to corporate social responsibility and is a member of the UN Global Compact. For more information, please visit www.zte.com.cn .
ZTE Microelectronics Technology had agreed to a $376 million investment by a national industry investment fund.
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
UNIPRINT.NET19.7.2018 09:37 | pressemeddelelse
Pat Johnson Joins UniPrint Team in Europe
POSEIDON-FOUNDATION19.7.2018 09:36 | pressemeddelelse
The Poseidon Foundation: Liverpool Bids to Be First ‘Climate Positive’ City by End of 2020
ELLIOTT-ADVISORS-(UK)19.7.2018 09:32 | pressemeddelelse
Elliott Advisors (UK) Statement on thyssenkrupp AG
FLEXTRADE19.7.2018 09:32 | pressemeddelelse
Albar Capital Deploys FlexNOW
MA-LOGIN-VSI19.7.2018 08:37 | pressemeddelelse
Login VSI Revolutionizes Application Compatibility Testing
TAKEDA-PHARMACEUTICAL19.7.2018 07:02 | pressemeddelelse
New Phase 3 Data Show Investigational Subcutaneous Formulation of Vedolizumab Meets Primary Endpoint in Achieving Clinical Remission at Week 52 in Patients with Moderately to Severely Active Ulcerative Colitis
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum